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Abstract: Background The European Rare Kidney Disease Reference Network (ERKNet) recently estab-
lished ERKReg, a Web-based registry for all patients with rare kidney diseases. The main objectives of
this core registry are to generate epidemiological information, identify current patient cohort for clinical
research, explore diagnostic and therapeutic management practices, and monitor treatment performance
and patient’s outcomes. The registry has a modular design that allows to integrate comprehensive
disease-specific registries as extensions to the core database. The diagnosis (Orphacode) and diagnostic
information (clinical, imaging, histopathological, biochemical, immunological and genetic) are recorded.
Anthropometric, kidney function, and disease-specific management and outcome items informing a set
of 61 key performance indicators (KPIs) are obtained annually. Data quality is ensured by automated
plausibility checks upon data entry and regular offline database checks prompting queries. Centre KPI
statistics and benchmarking are calculated automatically. Results Within the first 24 months since its
launch, 7607 patients were enrolled to the registry at 45 pediatric and 12 specialized adult nephrology
units from 21 countries. A kidney disease diagnosis had been established in 97.1% of these patients at time
of enrolment. While 199 individual disease entities were reported by Orphacode, 50% of the cohort could
be classified with 11, 80% with 43 and 95% with 92 codes. Two kidney diagnoses were assigned in 6.5%
of patients; 5.9% suffered from syndromic disease. Whereas glomerulopathies (54.8%) and ciliopathies
including autosomal dominant polycystic kidney disease (ADPKD) (31.5%) were the predominant disease
groups among adults, the pediatric disease spectrum encompassed congenital anomalies of the kidney and
urinary tract (CAKUT) (33.7%), glomerulopathies (30.7%), ciliopathies (14.0%), tubulopathies (9.2%),
thrombotic microangiopathies (5.6%), and metabolic nephropathies (4.1%). Genetically confirmed di-
agnoses were reported in 24% of all pediatric and 12% adult patients, whereas glomerulopathies had
been confirmed by kidney biopsy in 80.4% adult versus 38.5% pediatric glomerulopathy cases. Conclu-
sions ERKReg is a rapidly growing source of epidemiological information and patient cohorts for clinical
research, and an innovative tool to monitor management quality and patient outcomes.
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Abstract 
Background: The European Rare Kidney Disease Reference Network (ERKNet) recently established ERKReg, a Web-
based registry for all patients with rare kidney diseases. The main objectives of this core registry are to generate 
epidemiological information, identify current patient cohort for clinical research, explore diagnostic and therapeutic 
management practices, and monitor treatment performance and patient’s outcomes. The registry has a modular 
design that allows to integrate comprehensive disease-specific registries as extensions to the core database. The 
diagnosis (Orphacode) and diagnostic information (clinical, imaging, histopathological, biochemical, immunological 
and genetic) are recorded. Anthropometric, kidney function, and disease-specific management and outcome items 
informing a set of 61 key performance indicators (KPIs) are obtained annually. Data quality is ensured by automated 
plausibility checks upon data entry and regular offline database checks prompting queries. Centre KPI statistics and 
benchmarking are calculated automatically.
Results: Within the first 24 months since its launch, 7607 patients were enrolled to the registry at 45 pediatric and 
12 specialized adult nephrology units from 21 countries. A kidney disease diagnosis had been established in 97.1% 
of these patients at time of enrolment. While 199 individual disease entities were reported by Orphacode, 50% of 
the cohort could be classified with 11, 80% with 43 and 95% with 92 codes. Two kidney diagnoses were assigned in 
6.5% of patients; 5.9% suffered from syndromic disease. Whereas glomerulopathies (54.8%) and ciliopathies includ-
ing autosomal dominant polycystic kidney disease (ADPKD) (31.5%) were the predominant disease groups among 
adults, the pediatric disease spectrum encompassed congenital anomalies of the kidney and urinary tract (CAKUT) 
(33.7%), glomerulopathies (30.7%), ciliopathies (14.0%), tubulopathies (9.2%), thrombotic microangiopathies (5.6%), 
and metabolic nephropathies (4.1%). Genetically confirmed diagnoses were reported in 24% of all pediatric and 12% 
adult patients, whereas glomerulopathies had been confirmed by kidney biopsy in 80.4% adult versus 38.5% pediatric 
glomerulopathy cases.
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Background
Rare kidney diseases comprise more than 300 inherited, 
congenital or acquired disorders, which altogether affect 
at least two million European citizens [1]. More than ten 
percent of adults and nearly all children with end stage 
kidney disease (ESKD) suffer from a rare kidney disease 
[2]. The low disease incidence puts patients at risk of late, 
missed or erroneous diagnosis and delayed referral to 
expert centres and limits even the expertise of specialists, 
leading to suboptimal therapeutic management and com-
promised long-term outcomes.
The European Rare Kidney Disease Reference Network 
(ERKNet) is one of 24 European Reference Networks 
(ERNs) created by the European Union in 2017 [3]. ERK-
Net is a consortium of currently 32 pediatric and 20 adult 
nephrology centres with specific expertise in rare kidney 
diseases. ERKNet aims to improve the quality of patient 
management by systematic education of healthcare pro-
fessionals, the development and implementation of best 
practice guidelines, virtual expert consultations for chal-
lenging cases, and promotion of clinical research activi-
ties [4]. In order to document the clinical impact of their 
efforts, ERKNet members have committed to continu-
ously monitor key performance and outcome indicators 
(KPIs) in their patients.
Patient registries are a crucial component of patient 
management and clinical research in the rare disease area 
[5, 6]. An internal survey performed in 2017 revealed 
that the ERKNet centres were active in more than 60 
mostly disease-specific registries with mostly regional 
or national patient coverage or voluntary participation. 
None of the registries was used in all ERKNet centres and 
few provided monitoring of relevant disease or treatment 
specific performance and outcome measures. In order 
to counteract this fragmentation and improve the quan-
tity and quality of captured information, the Network 
decided to create the European Rare Kidney Disease Reg-
istry (ERKReg). Here, we provide a detailed report of the 
registry design and implementation and characterise the 
patient population assembled during the registry’s first 
2 years of operation.
Registry scope and objectives
ERKReg aims to collect disease and treatment related 
information from all patients with rare kidney diseases 
who are followed at expert centres. Core demographic 
and diagnostic information as well as selected disease- 
and treatment-specific prospective follow-up data are 
collected. The main objectives of the registry encompass 
the provision of demographic disease information, the 
assessment of natural and therapeutically modified dis-
ease outcomes, the identification of patient cohorts suit-
able for diagnostic and interventional research, and the 
longitudinal monitoring of participating centres regard-
ing disease-specific key performance and outcome indi-
cators. Moreover, the registry serves as a platform for 
sub-registries (registry studies) that will collect more 
detailed information on individual rare kidney diseases 
or disease groups.
Registry design and protocol
The contributing centres are requested to prospectively 
enrol all, both prevalent and incident, patients seen for 
the diagnostic and therapeutic management of a rare kid-
ney disease in the registry. The registry contains a basic 
and a follow-up module (Fig.  1). The basic section cap-
tures demographic and diagnostic information, as well 
as a ‘termination’ section where the date and causes of 
follow-up discontinuation can be entered. Patients with a 
suspected but as yet undiagnosed rare kidney disease can 
be provisionally entered in an abbreviated case report 
form, which can be transformed to a full entry once the 
diagnosis has been established. The follow-up module 
captures general information regarding kidney function, 
associated comorbidities and treatment related informa-
tion. In addition, selected disease-specific information is 
queried that allows to assess key performance and out-
come indicators. The longitudinal module is updated 
annually.
Registry population
All patients with a primary rare disease of the kidney or a 
syndromic disease associated with kidney manifestations 
are eligible for inclusion in the registry, irrespective of 
current age, age at disease presentation, disease duration, 
Conclusions: ERKReg is a rapidly growing source of epidemiological information and patient cohorts for clinical 
research, and an innovative tool to monitor management quality and patient outcomes.
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current kidney function and treatment status (conserva-
tive, dialysis, kidney transplantation). The main target 
disease groups include primary inherited and immune-
mediated glomerulopathies and tubulopathies, systemic 
disorders (metabolic diseases, vasculitis) affecting glo-
merular and/or tubular function, ciliopathies with a renal 
phenotype (including autosomal dominant polycystic 
kidney disease and autosomal recessive polycystic kidney 
disease), congenital anomalies of the kidney and urinary 
tract (CAKUT), thrombotic microangiopathies affecting 
the kidneys, and rare causes of arterial hypertension.
Participation in the ERKReg registry is a core com-
mitment of all member and Affiliated Partner centres of 
ERKNet. Completeness of recruitment is monitored by 
comparison of the cumulative enrolment figures with the 
numbers of total and incident patient figures provided by 
the centres at time of their application for membership or 
affiliation to ERKNet. In addition to the ERKNet mem-
ber and Affiliated partner sites, participation in ERKReg 
(and any sub-registries as described below) is also open 
to interested centres outside ERKNet.
Integration of rare kidney disease registry studies 
(sub‑registries)
The database has a modular structure that allows to 
integrate disease-specific sub-registries in which more 
detailed phenotype and prospective treatment and out-
come information is captured. The first sub-registry 
Fig. 1 Registry design and structure
Page 4 of 15Bassanese et al. Orphanet J Rare Dis          (2021) 16:251 
integrated in ERKReg is the distal renal tubular acidosis 
(dRTA) registry promoted by the European Society of 
Pedatric Nephrology (ESPN). When a patient with dRTA 
is enrolled in ERKReg, an optional sub-registry extension 
module with 29 additional data fields can be activated 
by the user. Further sub-registries for individual diseases 
(cystinuria, pediatric SLE nephritis) are currently under 
construction.
Data elements
The Registry is comprised of two datasets: A core data-
set is to be provided for all patients in the registry; it 
includes the Common Data Elements (CDE) defined 
by the Joint Research Centre (JRC) (Additional file  1: 
Table S1), as well as essential information relevant to all 
patients with rare kidney diseases such as the current 
kidney function (estimated glomerular filtration rate, 
eGFR) and treatment modality (conservative, dialysis, 
transplant) [7]. The Orphanet nomenclature is used to 
classify clinical diagnoses, and the Human Genome Vari-
ation Society (HGVS) terminology for the classification 
of gene variants.
In addition disease-specific data is captured, which 
comprises the diagnostic information on which the diag-
nosis is based, such as the genetic, histopathological, bio-
chemical and imaging features including the date when 
this information was obtained. Moreover, selected dis-
ease- or disease group-specific items are collected that 
allow monitoring a set of 61 key performance and out-
come indicators (KPIs) (Additional file 2: Table S2). The 
KPIs were selected by the ERKNet expert workgroups 
in an iterative Delphi consensus process, based on an 
analysis of the clinical practice guidelines endorsed by 
ERKNet.
The complete data dictionary of the Registry is avail-
able online (http:// erkreg- metad ata. erknet. org).
Data collection and data quality management
Data is collected and entered by trained medical staff 
at each contributing site into online case report forms 
accessible through the registry website (www. regis try. 
erknet. org). Conditional data entry menus are displayed 
based on the clinical diagnosis and patient age (pediatric 
or adult).
The users are trained in the use of the system by the 
registry coordination team in virtual workshops and reg-
ular ‘registry user days’. A user’s manual and FAQ docu-
ment are also available through the website, and user 
queries are answered by a registry helpdesk.
Automated data entry checks using pre-defined plausi-
bility ranges prevent saving of biologically or technically 
implausible data. As a second layer of quality control, 
more refined data consistency evaluations are performed 
and queries sent at regular intervals (e.g. implausible 
results for KPIs).
Data reporting and access
The general characteristics of the registry cohort, includ-
ing the distribution of the most common diagnoses, 
are published in Annual Reports posted on the registry 
website.
The local registry investigators can view continuously 
updated Key Performance Indicator statistics for the 
patients of their centre in comparison with the total reg-
istry patient cohort on the website (KPI benchmarking). 
In addition to the online reporting module, all investiga-
tors receive semi-annual reports of their centre’s current 
KPI statistics.
The registry investigators have continuous access to 
their own centre’s data, which can be downloaded using 
the export function of the platform. In addition, registry 
investigators of sites that enrolled at least 50 patients to 
the registry have access to a ‘Cohort Finder’ tool which 
allows to count patients by diagnosis or affected gene 
with an option to filter by current patient age, CKD 
(chronic kidney disease) stage and treatment modality.
Further data access by registry investigators and third 
parties is subject to review and approval by the Regis-
try Board (see below). Data access requests can be sub-
mitted using a request form. Only aggregated results or 
fully anonymized patient-level data are transmitted for 
research purposes.
Governance
The registry is governed by the Registry Board composed 
of the ERKNet Coordinator, four expert members from 
different thematic working groups of ERKNet, at least 
one representative of the sub-registries, the chair of the 
ERKNet Patient Advocacy Group (ePAG), and the chairs 
of the ERA-EDTA Working Group for Inherited Kidney 
Diseases (WGIKD) and the ESPN Working Group for 
Inherited Renal Disorders. The Registry Board is respon-
sible for organizing and supervising the conduct of the 
registry. It defines the annual report contents and decides 
about internal and external data analysis requests. The 
Registry Board also serves as the primary contact for 
interactions with sponsors.
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Data privacy and protection
All patient data are entered and stored in a pseu-
donymised fashion. Only the authorized local user is 
able to identify the patient through an identification 
code, automatically generated at the time of patient 
registration. Access of authorized users to the registry 
is controlled by assignment of a secure, individualized 
password. A hierarchical access authorization system is 
implemented with super-administrator, administrator 
and centre user levels.
The Registry is fully compliant with the Note for Guid-
ance on Good Clinical Practices (CPMP/ICH/135/95) 
[8], the EU General Data Protection Regulation (GDPR) 
[9] and any national rules and regulations regarding 
data protection. The informed consent form, based on a 
generic template provided by the EU for use by the ERNs, 
was approved by the local institutional review boards as 
required by local and national regulations.
Data sharing agreements defining the terms and condi-
tions of participation in the Registry were signed by Hei-
delberg University Hospital, the registry lead institution, 
and each contributing centre.
Technical implementation
The registry website was programmed in HTML/PHP, 
CSS and JavaScript. The data is stored in a SQL database 
hosted on a commercial server (IONOS 1&1, Montabaur, 
Germany), inaccessible to non-authorized personnel or 
entities. Regular back-ups of the database are made.
Results
Registry participation
After the launch of the registry in January 2019, both 
ERKNet and external centres gradually started enroll-
ing patients (Fig.  2). The number of active healthcare 
providers (HCPs) was 25, 30, 36, and 49 at the end 
of the second and fourth quarters of 2019 and 2020, 
respectively. The participating HCPs comprise 27 
ERKNet members (contributing 92.5% of patients), 6 
ERKNet Affiliated Partners (5.2% of patients), and 16 
external centres (2.3% of patients).
The centres are located in 21 countries, including 
Italy (n = 11), Germany (n = 6), Turkey (n = 6), France 
(n = 4), the Netherlands (n = 2), Belgium (n = 2), 
Greece (n = 2), Spain (n = 2), Slovenia (n = 2), Aus-
tria, Czechia, Denmark, Hungary, Iran, Ireland, Latvia, 
Lithuania, Poland, Russia, the UK, and the UAE (n = 1 
each). While the largest contributing countries in terms 
of absolute patient numbers were Italy (n = 2340), 
France (n = 1938) and Germany (n = 1143), the high-
est number of patients relative to population size was 
enrolled in Slovenia (16.2 per million population, pmp) 
and Lithuania (10.7 pmp) (Fig. 3).
Contributions are received from 45 pediatric and 12 
adult nephrology units, with both pediatric and adult 
nephrology units being active at 7 HCPs. Data entries 
have been made by 101 individual users to date, with a 
single user being active in 27 centres, two users in eight 
centres, three users in four centres, four users in four 
centres, five users in three centres, seven users in one and 
eight users in one centre.
Renal diagnoses
The Orphacode classification system was adopted for 
the assignment of diagnoses. A total of 335 Orphacodes 
designating kidney diseases or systemic disorders with 
a renal phenotype were identified from the thesaurus 
[10]. In addition, 21 entities currently not represented 
in the Orphacode system were included in the selection; 
these included several “not otherwise specified” and “by 
other cause” sub-categories which are not supported by 
OrphaNet. The complete rare kidney disease catalogue 
can be downloaded from the ERKReg website [11].
Out of 7607 patients enrolled to date, 7385 (97.1%) 
have an established kidney disease diagnosis. Of the 
335 renal disease codes, 199 were utilized to code these 
patients. As shown in Fig. 4, 50% of the patient popula-
tion could be classified with 11 codes, 80% with 43 codes 
and 95% with 92 codes. The 92 most common renal dis-
ease codes are listed in Table 1.
In order to correctly capture complex diseases, in par-
ticular those with congenital anomalies of the kidneys 
Fig. 2 Cumulative patient enrolment in ERKReg registry
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and the urinary tract (CAKUT), assignment of up to 
two disease codes per patient is allowed. So far a second 
renal diagnosis has been coded in 481 subjects (6.5%), 
thereof 436 CAKUT patients. In 104 of the 1781 CAKUT 
patients (5.9%) the renal phenotype is part of a defined 
syndromic disorder.
Patient population
The characteristics of the registry cohort collected 
during the first 2 years of the registry are summarized 
in Table  2. Structural kidney disorders (CAKUT and 
ciliopathies) and—acquired and hereditary—glomeru-
lopathies represented the largest groups of rare kidney 
diseases regarding the numbers of patients and disease 
entities. Male gender was overrepresented in CAKUT, 
glomerulopathies (67% males in IgA nephropathy, 
66% in membranous nephropathy, 62% in idiopathic 
steroid sensitive nephrotic syndrome), and metabolic 
nephropathies (because of male-exclusive Lowe 
syndrome).
A family history for kidney disease was most com-
monly reported in ciliopathies (ADPKD), tubulopa-
thies (nephrogenic diabetes insipidus) and metabolic 
nephropathies (X-linked hypophosphatemia). Genetic 
screening was performed in 26% of all patients and 46% 
of those with a hereditary disease diagnosis. A genetic 
disease cause was confirmed by testing in 20% of all 
patients and 40% of those with a hereditary disease. The 
mutation detection rate ranged from 96% in rare causes 
of hypertension and 94% in metabolic nephropathies to 
52% in CAKUT disorders. Histopathological confirma-
tion was obtained in 57% of glomerulopathies but was 
performed very rarely (0–2%) in CAKUT, ciliopathy 
and tubulopathy cases.
The disease groups distinctly differed with regards to 
global kidney function at time of enrolment: End-stage 
kidney disease was present in 22% of CAKUT, 21% of 
Fig. 3 Centers and European countries contributing to the registry. Symbol size reflects number of patients enrolled per center. Country colours 
indicate number of patients enrolled per million population (see legend). Patient contribution from non-European countries (4 countries, 88 
patients) is not included in the graph
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ciliopathy and 19% of thrombotic microangiopathy and 
metabolic nephropathy cases, as compared to 13% of glo-
merulopathies and 3% of patients with tubulopathies.
Pediatric and adult disease characteristics
The distribution of rare kidney diseases differed mark-
edly between pediatric and adult patients: whereas glo-
merulopathies (54.8%) and ciliopathies (31.5%, thereof 
87.8% ADPKD) were the most common rare kidney dis-
eases treated in adult nephrology units, the vast major-
ity of CAKUT, tubulopathy, metabolic nephropathy and 
thrombotic microangiopathy patients were reported by 
pediatric units (Fig.  5). The distribution of patient age 
at time of enrolment is depicted in Fig. 6.
The proportion of genetic testing was 14% and 31% of 
all adult and pediatric patients, respectively. When con-
sidering only the genetic disease cases, the proportion 
of patients who underwent genetic testing was 28% in 
adults and 54% in pediatric patients. Pediatric patients 
had a genetically confirmed diagnosis twice as often as 
adult patients (24 vs 12%, Fig.  7). The most common 
genetically confirmed diagnoses were ADPKD, Alport 
syndrome, distal renal tubular acidosis, ARPKD and 
genetic steroid resistant nephrotic syndrome in pediat-
ric patients and ADPKD, Alport syndrome, Fabry dis-
ease and Gitelman syndrome in adults.
In adults the renal diagnosis was secured by kidney 
biopsy in 44% of all cases as compared to 13% in pediat-
ric patients. When considering only glomerulopathies, 
kidney biopsies were performed in 80.4% of the adult 
as compared to 38.5% of the pediatric cases. The most 
common histopathological diagnoses in adults were 
membranous nephropathy, IgA nephropathy, focal seg-
mental glomerulosclerosis (FSGS), membranoprolifera-
tive glomerulonephritis (MPGN) and Lupus nephritis, 
and in pediatric patients, minimal change nephropathy, 
IgA nephropathy, FSGS and MPGN.
More than half of the pediatric patients had normal 
kidney function (54.8% CKD stage 1 vs 24% in adults) 
whereas the majority of adults were in CKD stage 2–4 
(62% vs 28%). Similar fractions of patients had attained 
end-stage kidney disease at time of registry enrolment 
(pediatric: 17.8% vs adult: 13.6%).
Discussion
ERKReg is among the first registries constructed by a 
European Reference Network to capture essential infor-
mation from patients with all diagnoses in the the-
matic areas of interest. Since its launch in early 2019, 
the European Rare Kidney Disease Registry has rapidly 
grown to become the largest single database of patients 
with rare and complex kidney disorders assembled to 
date. With its well defined objectives, user friendly 
design and focused data collection, the registry has 
been well accepted and rapidly implemented by most 
consortium partners.
Some 300 rare disease entities with a renal phenotype 
are defined in the Orphanet classification system [10]. As 
expected, a highly asymmetric prevalence distribution of 
the individual kidney diseases was found, with 11 diag-
noses covering 50% and 190 codes the other half of the 
population. Another 100 listed diseases are so rare that 
no cases were reported among the first 7600 patients. 
These findings reconfirm the need for large consortium 
of specialized healthcare services to join forces in order 
to collect sufficiently sized patient cohorts with rare and 
ultrarare kidney diseases for clinical research.
Based on patient counts performed when the ERKNet 
centres applied for membership, an estimated 25–30% 
of all available patients have been enrolled on average 
by the active centres to date, leaving room for further 
growth. Furthermore, the size of the ERKNet consortium 
is expected to nearly double in 2021 as some 30 centres 
with more than 30,000 patients have applied for ERK-
Net membership in the ongoing second call. All appli-
cant sites have committed to enrolling their patients to 
ERKReg. Finally, the registry is also open to non-ERKNet 
sites, and a growing number of sites in non-EU countries 
Fig. 4 Cumulative fraction of patients identified with a given number 
of diagnoses ranked by frequency
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Table 1 The 92 most common individual diagnoses, covering 95% of the registry cohort. Codes marked with an asterisk are internal 
codes for entities currently not represented in OrphaNet
Orphacode Diagnosis N % Pediatric Adult
CAKUT (OC 93545) 1781 23.4 1719 62
93110 Posterior urethral valve 258 3.3 254 4
93173 Renal dysplasia, bilateral 227 2.9 224 3
9999969* Vesicoureteric reflux, high-grade 216 2.8 197 19
2190 Congenital hydronephrosis 159 2.1 158 1
93100 Renal agenesis, unilateral 130 1.7 124 6
97363 Unilateral multicystic dysplastic kidney 121 1.6 121
97362 Renal hypoplasia, bilateral 103 1.4 98 5
93172 Renal dysplasia, unilateral 84 1.1 85
97361 Renal hypoplasia, unilateral 76 1.0 73 2
97364 Bilateral multicystic dysplastic kidney 60 0.8 59 1
9999968* Neurogenic bladder, congenital or acquired 58 0.8 57 1
289365 Vesicoureteric reflux, familial 36 0.5 30 6
93111 RCAD (Renal cysts and diabetes) syndrome 34 0.4 33 1
9999985* Ureteropelvic junction obstruction (bilateral or in solitary kidney) 30 0.4 29 1
887 VACTERL/VATER association 19 0.2 19
238646 Congenital primary megaureter, obstructed form 19 0.2 19
238650 Congenital primary megaureter, refluxing form 18 0.2 18
238654 Congenital primary megaureter, nonrefluxing and unobstructed form 14 0.2 14
2970 Prune belly syndrome 14 0.2 14
238637 Megacystis-megaureter syndrome 10 0.1 9 1
567 Di George syndrome (22q11.2 deletion) 10 0.1 10
107 BOR (branchio-oto-renal) syndrome 7 0.09 6 1
9999986* Congenital primary megaureter, refluxing and obstructed 7 0.09 6 1
2237 HDR (Hypoparathyroidism-deafness-renal disease) syndrome 7 0.09
Ciliopathies (OC 93587) 1406 18.4 684 722
730 Autosomal dominant polycystic kidney disease 945 12.4 312 633
731 Autosomal recessive polycystic kidney disease 150 2.0 146 4
805 Tuberous sclerosis complex 67 0.9 40 27
110 Bardet–Biedl syndrome 58 0.8 22 36
93592 Juvenile nephronophthisis 56 0.7 55 1
93591 Infantile nephronophthisis 32 0.4 31 1
93111 RCAD (Renal cysts and diabetes) syndrome 24 0.3 18 6
2318 Joubert syndrome with oculorenal defect 15 0.2 15
Glomerulopathies (OC 93548) 2816 37.0 1561 1255
69061 Idiopathic steroid-sensitive nephrotic syndrome 643 8.5 540 130
9999982* IgA nephropathy 368 4.8 103 265
97560 Membranous nephropathy 346 4.6 25 321
88917 Alport syndrome, X-linked 219 2.9 159 60
567546 Idiopathic steroid-sensitive nephrotic syndrome with secondary steroid 
resistance
95 1.2 48 47
656 Genetic steroid-resistant nephrotic syndrome 92 1.2 86 6
567552 Idiopathic steroid-resistant nephrotic syndrome with sensitivity to 
second-line immunouppressive therapy
90 1.2 76 14
536 SLE nephritis 78 1.0 11 67
329931 C3 glomerulonephritis 75 1.0 58 17
761 Immunoglobulin A vasculitis (Henoch Schönlein nephritis) 67 0.9 60 7
567550 Idiopathic multidrug-resistant nephrotic syndrome 56 0.7 35 21
93552 Pediatric systemic lupus erythematosus 49 0.7 49
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Table 1 (continued)
Orphacode Diagnosis N % Pediatric Adult
567544 Idiopathic non-lupus full-house nephropathy 49 0.7 15 34
9999975* Immune complex associated membranoproliferative glomerulonephritis, 
not otherwise specified
48 0.6 23 25
97563 Pauci-immune glomerulonephritis with ANCA 44 0.6 16 28
88918 Alport syndrome, autosomal dominant 43 0.6 16 27
97556 Congenital nephrotic syndrome, no genetic cause specified 37 0.5 35 2
839 Congenital nephrotic syndrome, Finnish type 36 0.5 36
88919 Alport syndrome, autosomal recessive 35 0.5 23 12
900 Granulomatosis with polyangiitis 34 0.5 6 28
329903 Immunoglobulin-mediated membranoproliferative glomerulonephritis 30 0.4 8 22
220 Denys–Drash syndrome 29 0.4 29
727 Microscopic polyangiitis 27 0.3 3 24
9999976* Microscopic (including familial) hematuria 23 0.3 16 7
97564 Pauci-immune glomerulonephritis without ANCA 17 0.3 5 12
91138 Cryoglobulinemic vasculitis 17 0.2 17
85445 AA amyloidosis 14 0.2 14
93571 Dense deposit disease 14 0.2 11 3
9999972* Nephrotic syndrome, syndromic, not otherwise specified 13 0.2 13
9999977* Collagenopathy, not further specified 13 0.2 1 12
85443 AL amyloidosis 11 0.1 11
Tubulopathies (OC 93603) 681 8.9 539 141
402041 Autosomal recessive distal renal tubular acidosis 139 1.8 133 6
358 Gitelman syndrome 82 1.0 52 30
214 Cystinuria 81 1.0 31 50
112 Bartter syndrome 76 0.9 64 12
2197 Hypercalciuria, idiopathic 53 0.7 43 10
89936 X-linked hypophosphatemia 45 0.6 45
223 Nephrogenic diabetes insipidus 43 0.6 36 7
93608 Autosomal dominant distal renal tubular acidosis 34 0.4 32 2
3337 Fanconi syndrome, primary 19 0.2 14 5
91500 Tubulointerstitial nephritis and uveitis syndrome 16 0.2 12 4
31043 Familial primary hypomagnesemia with hypercalciuria and nephrocalci-
nosis
14 0.2 13 1
9999967* Fanconi syndrome, induced by other drug 10 0.1 10
Thrombotic Microangiopathies (OC 93573) 321 4.2 283 38
90038 Shiga toxin-associated hemolytic uremic syndrome 167 2.2 165 2
544472 Atypical hemolytic uremic syndrome with complement gene abnormal-
ity
57 0.7 46 11
9999987* Atypical hemolytic uremic syndrome, not further specified 48 0.6 31 17
93581 Atypical hemolytic uremic syndrome with anti-factor H antibodies 19 0.2 18 1
544493 Streptcoccous pneumoniae-associated hemolytic uremic syndrome 11 0.1 11
93585 Acquired thrombotic thrombocytopenic purpura 7 0.1 2 5
Metabolic Nephropathies (OC 93593) 302 3.9 233 69
411629 Infantile nephropathic cystinosis 84 1.1 67 17
93598 Primary hyperoxaluria type 1 53 0.7 50 3
324 Fabry disease 32 0.4 5 27
534 Lowe syndrome 24 0.3 23 1
93622 Dent disease type 1 (CLCN5-related) 22 0.3 17 5
300547 Autosomal recessive infantile hypercalcemia 18 0.2 16 2
27 Methylmalonic acidemia, Vitamin B12-unresponsive 18 0.2 16 2
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have recently started contributing to the Registry. Hence, 
rapid further growth of the registry is expected.
The ERN registries are committed to the FAIR princi-
ples, i.e. aiming to make their databases findable, acces-
sible, interoperable, and re-usable [12, 13]. The ERKReg 
registry website, metadata information including the reg-
istry’s data dictionary, and information about data access 
rules and procedures can easily be found by searching the 
Web. In addition, ERKReg is registered in the OrphaNet 
registry database and the European Rare Disease Registry 
Infrastructure (ERDRI) [14]. The metadata deployment 
of the registry’s data fields in the ERDRI.mdr repository 
is currently in progress. The integration of the Common 
Data Elements released by the EU’s Joint Research Cen-
tre (JRC) is an essential component of making the regis-
try data interoperable [7] (Additional file 1: Table S1). An 
application programming interface (API) for automated 
processing of data queries through the emerging Vir-
tual Platform of the European Joint Programme on Rare 
Diseases (EJP RD) is planned. In this way it is ensured to 
maximize the usefulness of the registry for the rare dis-
ease research community.
The presented summary of the baseline characteristics 
of the 7607 patients enrolled so far provides an estimate 
of the relative frequency of rare kidney disease groups 
and individual kidney diseases seen at specialized cen-
tres. In children, congenital anomalies of the kidney and 
urinary tract (CAKUT) and glomerulopathies represent 
the most common disease groups. In adult patients, 
glomerulopathies constitute the most common disease 
group, whereas ADPKD is the most common individual 
disease entity. The other main categories of rare kidney 
diseases, i.e. tubulopathies, metabolic nephropathies and 
thrombotic microangiopathies, altogether comprise only 
21% of the patients seen in the pediatric and 11% of those 
in the adult nephrology units. This information, reflect-
ing the relative clinical experience of rare kidney disease 
specialists with different types of disorders, is useful for 
the planning of educational but also clinical research 
activities by ERKNet and the rare kidney disease commu-
nity at large.
A unique feature of ERKReg is the KPI monitoring 
module. The selective, disease-specific capture of infor-
mation concerning diagnostic and therapeutic man-
agement and outcomes is an efficient way to monitor 
clinical guideline adherence and patient outcomes. The 
KPIs were carefully selected by ERKNet experts in an 
iterative consensus process. The information of the clini-
cians regarding their centre’s performance in compari-
son with the registry averages (benchmarking, Fig.  8) is 
hoped to lead to gradual harmonization and optimiza-
tion of patient management and improve patient out-
comes across the Network. Concretely, such beneficial 
effects could encompass earlier genetic diagnostics to 
avoid ineffective and toxic immunosuppressive treat-
ments, improved long-term preservation of kidney func-
tion by strict blood pressure control and pharmacological 
nephroprotection, minimized secondary morbidity by 
stringent compensation of tubular electrolyte and water 
losses, early treatment of bone-mineral disorder and 
renal anemia, and prevention of irreversible growth fail-
ure by growth promoting therapies in children.
ERKReg is designed as a core registry to identify 
patient cohorts for clinical research but does not include 
comprehensive data collection for individual disorders. 
However, thanks to its modular design ERKReg allows 
extended data collection in individual rare diseases of 
interest. For patients with a certain diagnosis enrolled 
in ERKReg, expanded eCRFs can optionally be selected. 
This concept has been applied successfully with a sub-
registry for distal renal tubular acidosis and further dis-
ease-specific registries are under development. Hence, 
beyond its core purposes, ERKReg has the potential to 
become a platform for rare kidney disease registries.
The project has been facing several barriers and chal-
lenges (Table 3). Highly diverse feedback was received 
from the local Ethics Committees, ranging from no 
need for approval of a registry mainly serving health-
care optimization to requirements identical to a clinical 
trial including patient insurance despite no interven-
tions being performed. The current fragmentation of 
ethics standards and evaluation processes across the 
Table 1 (continued)
Orphacode Diagnosis N % Pediatric Adult
411634 Juvenile nephropathic cystinosis 11 0.1 9 2
Rare Causes of Hypertension (OC 93618) 79 1.0 75 4
97598 Renal artery stenosis, congenital 41 0.5 38
904 Williams syndrome 19 0.2 19
636 Neurofibromatosis type 1 12 0.2 11 1
Percent values relate to total number of patients in registry (N = 7607)
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Table 2 Characteristics of registry cohort




Rare causes of 
hypertension
All patients
No. of diagnoses (Orphacodes) 48 21 60 35 20 9 6 203
No. of patients (N (%)) 1781 
(24.1%)
1406 (19.0%) 2816 (38.1%) 680 (9.2%) 302 (4.1%) 321 (4.3%) 79 (1.1%) 7385 (100%)
Male sex (%) 68.5 47.3 56.5 52.4 57.6 51.1 49.3 57.0
Ethnicity (%)-Caucasian/Arabic/Afri-
can/East Asian/other
86/8/3/1/2 93/4/1/1/1 90/5/2/2/1 79/9/2/1/9 81/13/1/2/3 90/4/3/0/3 86/9/0/0/5 87/6/2/1/4
Family history of kidney diseases (%) 5.3 46.1 11.4 21.7 16.9 3.4 11.4 16.8
Median (IQR) age at first signs or 
symptoms (years)
0.0 (0.0–0.2) 11.1 (0.6–28.0) 11.6 (3.8–41.0) 1.7 (0.2–9.2) 0.8 (0.1–2.9) 3.3 (1.3–6.9) 1.2 (0.3–4-4) 14.1(7.4–
31.7)






17.8 (10.7–50.9) 12.3 (6.6–18.7) 15.0 (7.8–24.5) 8.9 (4.7–14.9) 11.0 (6.4–14.9) 4.8 (0.3–18.5)
Genetic testing performed (% of 
all cases)
11.3 38 17.3 62.1 61.9 22.1 31.6 26.1
Genetic testing performed (% of 
hereditary disease cases)
21.2 38 60.7 65.2 61.9 72.3 58.5 46.3
Genetically confirmed diagnosis (% 
of all cases)
5.3 31.9 12.1 54.7 57.9 15.9 29.1 20.4
Genetically confirmed diagnosis (% 
of hereditary disease cases)
11.2 31.9 52.1 57.6 57.9 56.6 56.1 39.7
Genetically confirmed diagnosis (% 
of hereditary disease cases who 
underwent genetic screening)
52.0 84.1 85.5 88.2 93.6 78.3 95.8 85.8
Histopathologically confirmed 
diagnosis (%)
0.8 1.1 57.1 2.2 6.6 14.0 0 23.2


















Data are median (interquartile range) or N (%) as applicable
EU member states and the local institutions is a major 
hurdle for EU-wide patient registries. While we even-
tually succeeded in meeting all individual demands, 
variable delays occurred that explain in part the rather 
heterogeneous national population coverage at this 
early stage of the registry’s operation as shown in Fig. 3. 
Furthermore, since ERKReg is expert centre- but not 
population-based, the registry cannot provide exact 
demographic figures about individual rare kidney dis-
eases; this task will continue to require regional or 
national databases with compulsory/automated report-
ing by healthcare providers.
Another source of variation in the uptake of the reg-
istry were differences in available local expertise and 
available resources to organize the participation in an 
international registry. We tried to minimize local efforts 
by limiting data collection to the minimally required 
dataset, designing a user-friendly website and electronic 
case report form, training the local staff in videocon-
ferences and by providing supportive material (such as 
a user guide and FAQ document) and establishing an 
online helpdesk. While these measures were largely suc-
cessful, the registry still tended to be implemented more 
rapidly in pediatric than adult nephrology sites due 
to the pediatric centres’ frequently better staffing and 
greater familiarity with collaborative data collection. This 
resulted in a relative enrichment of pediatric over adult 
patients in the early phase of the registry. It is hoped 
that this imbalance will be largely compensated in the 
near future, in particular in view of the preponderance 
of adult nephrology sites applying in the ongoing second 
ERN call. Also, some ascertainment bias may have been 
caused by preferential enrolment of patients in rare kid-
ney disease outpatient clinics with relatively short disease 
history and preserved kidney function. We hope that as 
the registry matures, patients with long-standing disease 
followed in dialysis units and transplant clinics will be 
progressively included as well.
Despite our efforts to minimize the data entry work-
load, the registry currently requires manual data submis-
sion. Automated data transmission is not (yet) possible 
due to the highly variable data structure and complete-
ness at the centre level and the fragmentation of hospital 
IT systems. Pilot efforts to represent the JRC Common 
Data Elements in the electronic health records are cur-
rently starting in individual institutions. It is hoped that 
these activities will facilitate at least partially automated 
data capture in the foreseeable future.
The development of ERKReg parallels the efforts 
to establish registries in all 24 ERNs. The anticipated 
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Fig. 5 Distribution of disease groups in adult and pediatric patients
Fig. 6 Distribution of age at time of enrolment per disease group
Table 3 Future objectives and challenges of the European Rare Kidney Disease Registry and disease-specific sub-registries
Objectives Challenges
Epidemiology of rare kidney diseases
Information on level of diagnostic ascertainment (inc. access to genetic 
testing)
Phenotype and natural history information
Continuous monitoring of diagnostic and therapeutic performance and 
guideline adherence for optimized patient outcomes
Rapid identification of patient cohorts for clinical trials
Ensuring unbiased representation of the European rare kidney disease 
population
Integration of EUPID pseudonymization system
Link with electronic health records for automated data transmission
Integration of quality of life data/disease-group specific patient reported 
outcome measures (PROMs)
Long-term sustainability of registry
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interoperability of the ERN registries will allow to search 
for patient groups with overlapping phenotypes that may 
be respresented in different ERN databases via the virtual 
platform developed by the EJP-RD consortium.
In conclusion, ERKNet has successfully created and 
implemented the European Rare Kidney Disease Regis-
try as a core database comprising a representative sample 
of patients treated for rare kidney diseases in highly spe-
cialized pediatric and adult nephrology units throughout 
Europe. The availability of a single database comprising 
currently treated patients with more than 200 individual 
kidney diseases is hoped to expedite the identification of 
patient cohorts available for diagnostic, prognostic and 
therapeutic research.
Fig. 7 Characteristics of pediatric and adult patients. CKD chronic kidney disease stage
Fig. 8 Example of Key Performance Indicator statistics and benchmarking feature as displayed on the Website to centre users
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